ERBB2 and interstitial lung disease: Although T‐DXd has manifested the best clinical efficacies in previously treated HER2‐positive lung cancer, it is the only approved HER2‐targeted drug and the TRAEs driven by T‐DXd have a high incidence of grade ≥3 TRAEs (46%) and interstitial lung disease (26%).16